V. Cassibba

发表

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

T. Barbui, A. Bosi, A. Gallamini, 2009, Blood.

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

A. Cortelezzi, F. Ciceri, A. Rambaldi, 2014, Blood Cancer Journal.

Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.

G. Pizzolo, G. Nadali, A. Ambrosetti, 1994, Leukemia.

Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation

A. Alberti, G. Meloni, E. Morra, 2003, Bone Marrow Transplantation.

Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes

G. Pizzolo, A. Ambrosetti, F. Vinante, 2006, Hematological oncology.

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

A. Vitale, M. Fumagalli, M. Ladetto, 2016 .

Aggressive LGL leukaemia presentation in old age

A. Piccin, R. Zambello, S. Cortelazzo, 2011, Annals of Hematology.

Acute Obstructive Hydrocephalus during Chemotherapy in T-Lymphoblastic Lymphoma

A. Piccin, A. Schwarz, M. Casini, 2016 .

Anti-thrombin-III reduction and posterior reversible encephalopathy syndrome (PRES) in acute lymphoblastic leukaemia (ALL). New insight into PRES pathophysiology

A. Piccin, S. Cortelazzo, V. Cassibba, 2011, Annals of Hematology.

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia

M. Fumagalli, A. Gallamini, G. Rossi, 2015, Haematologica.

S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

R. Foà, S. Chiaretti, A. Vitale, 2022, HemaSphere.

Case Burkitt’s Lymphoma of the Stomach: A Case Report and Review of the Literature

A. Mega, M. Casini, V. Cassibba, 2015 .

Genetics of destemming in pepper: A step towards mechanical harvesting

Kevin M. Stoffel, T. Hill, A. Van Deynze, 2023, Frontiers in Genetics.

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL)

M. Fumagalli, A. Gallamini, A. Cortelezzi, 2013 .

High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program

A. Levis, G. Rossi, E. Angelucci, 2013, Haematologica.

Lymphoblastic Leukemia (all) Molecular Study of Minimal Residual Disease (mrd) in Adult Acute Improved Risk Classification for Risk-specific Therapy Based on The

T. Barbui, A. Bosi, A. Gallamini, 2022 .

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

T. Barbui, A. Bosi, A. Gallamini, 2009 .

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

R. Foà, S. Chiaretti, A. Vitale, 2023, Blood advances.

Anti-thrombin-III reduction and posterior reversible encephalopathy syndrome (PRES) in acute lymphoblastic leukaemia (ALL). New insight into PRES pathophysiology

A. Piccin, S. Cortelazzo, V. Cassibba, 2011, Annals of Hematology.